p53-dependent Chk1 phosphorylation is required for maintenance of prolonged G2 arrest

Radiation Research

Volumn 168, Issue 6, 2007, Pages 706-715

  Wang, Xiao Qi ^a,b   Stanbridge, Eric J ^a   Lao, Xiaoyan ^a   Cai, Qi ^b   Fan, Sheung Tat ^b   Redpath, J Leslie ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; CAFFEINE; CHECKPOINT KINASE 1; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; PROTEIN P53; STAUROSPORINE; 7-HYDROXYSTAUROSPORINE; CDC25A PROTEIN, HUMAN; CHECKPOINT KINASE 2; DRUG DERIVATIVE; PROTEIN KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DRUG INHIBITION; DRUG TARGETING; FIBROBLAST; GAMMA RADIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; CELL LINE; DOWN REGULATION; DRUG EFFECT; GENETICS; METABOLISM; PHOSPHORYLATION; RADIATION EXPOSURE;

CAFFEINE; CDC25 PHOSPHATASES; CELL LINE; DOWN-REGULATION; G2 PHASE; HUMANS; PHOSPHORYLATION; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; STAUROSPORINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 38849208560     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1075.1     Document Type: Article

References (27)

1. J. Bartek and J. Lukas, Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3, 421-429 (2003).
2. B. B. Zhou and J. Bartek, Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat. Rev. Cancer 4, 216-225 (2004).
3. R. T. Abraham, Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15, 2177-2196 (2001).
4. 2/M checkpoints are induced by ionizing irradiation. Mol. Cell Biol. 22, 1049-1059 (2002).
5. A. J. Levine, p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
6. 2 checkpoint abrogation. Cancer Res. 59, 5887-5891 (1999).
7. H. Dixon and C. J. Norbury, Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function. Cell Cycle 1, 362-368 (2002).
8. 2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 3, 513-519 (2004).
9. 2-checkpoint inhibitor. Clin. Cancer Res. 2, 791-797 (1996).
10. R. G. Shao, C. X. Cao, T. Shimizu, P. M. O'Connor, K. W. Kohn and Y. Pommier, Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. 57, 4029-4035 (1997).
11. 2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 88, 956-965 (1996).
12. A. Blasina, B. D. Price, G. A. Turenne and C. H. McGowan, Caffeine inhibits the checkpoint kinase ATM. Curr. Biol. 9, 1135-1138 (1999).
13. J. N. Sarkaria, E. C. Busby, R. S. Tibbetts, P. Roos, Y. Taya, L. M. Karnitz and R. T. Abraham, Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 59, 4375-4382 (1999).
14. S. L. Yao, A. J. Akhtar, K. A. McKenna, G. C. Bedi, D. Sidransky, M. Mabry, R. Ravi, M. I. Collector, R. J. Jones and A. Bedi, Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat. Med. 2, 1140-1143 (1996).
15. 2/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity. J. Biol. Chem. 275, 10342-10348 (2000).
16. S. W. Tam and R. Schlegel, Staurosporine overrides checkpoints for mitotic onset in BHK cells. Cell Growth Differ. 3, 811-3817 (1992).
17. S. Fan, M. L. Smith, D. J. Rivet, D. Duba, Q. Zhan, K. W. Kohn, A. J. Fornace and P. M. O'Connor, Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55, 1649-1654 (1995).
18. 2 delay. Cancer Res. 55, 1643-1648 (1995).
19. 1 checkpoint-competent cells. Cancer Res. 55, 1639-1642 (1995).
20. A. Eastman, Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J. Cell Biochem. 91, 223-231 (2004).
21. 2 cell cycle checkpoints. Oncogene 24, 3786-3796 (2005).
22. 2-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res. 62, 5743-5748 (2002).
23. 1-phase arrest: TP53-dependent and TP53-independent roles. Radiat. Res. 159, 72-85 (2003).
24. X. Q. Wang, J. L. Redpath, S. T. Fan and E. J. Stanbridge, ATR dependent activation of Chk2. J. Cell Physiol. 208, 613-619 (2006).
25. M. S. Chen, C. E. Ryan and H. Piwnica-Worms, Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol. Cell Biol. 23, 7488-7497 (2003).
26. 2/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J. 21, 5911-5920 (2002).
27. 2 checkpoint is retinoblastoma protein dependent. Mol. Cell Biol. 20, 4210-4223 (2000).